|
| Tuesday, October 31, 2017 |
|
|
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase |
| Eisai Co., Ltd. announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4. more info >> |
|
| Tuesday, October 24, 2017 |
|
|
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer's disease treatments. more info >> |
|
| Friday, October 13, 2017 |
|
|
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan |
| Eisai Co., Ltd., Toyama Chemical Co., Ltd. of the Fujifilm Group and Taisho Pharmaceutical Co., Ltd. today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. more info >> |
|
|
エーザイ・富山化学・大正製薬、抗リウマチ剤「コルベット(R)錠 25mg」の日本における製造販売承認の承継と販売移管に合意 |
| エーザイ株式会社と富士フイルムグループの富山化学工業株式会社、大正製薬株式会社は、このたび、抗リウマチ剤「コルベット(R)錠 25mg」（一般名：イグラチモド）に関して、日本におけるエーザイによる製造販売承認の承継ならびにエーザイへの販売移管について合意したことをお知らせします。 more info >> |
|
| Wednesday, October 11, 2017 |
|
|
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond |
| Eisai Co., Ltd. will launch Onji-no-Megumi (category-3 OTC drug), a medicine for improving forgetfulness in middle age and beyond, on October 10 (Tuesday) at pharmacies and drugstores countrywide. more info >> |
|
| Tuesday, October 10, 2017 |
|
|
エーザイ、中年期以降のもの忘れ改善薬「遠志（オンジ）の恵み(R)」新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、中年期以降のもの忘れ改善薬「遠志の恵み(R)」（第 3 類医薬品）を本日、10 月 10 日（火）に全国の薬局・薬店、ドラッグストアにて新発売します。 more info >> |
|
| Wednesday, October 4, 2017 |
|
|
エーザイ、Biotoscana社と中南米における独占的ライセンス契約を締結 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、米国子会社であるエーザイ・インクが、Grupo Biotoscana（本社：ウルグアイ、CEO：Mariano Garcia-Valino、以下Biotoscana社）と、中南米におけるがん領域および神経領域製品を対象とする独占的ライセンス契約を締結したことをお知らせします。 more info >> |
|
|
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America |
| Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America. more info >> |
|
| Tuesday, October 3, 2017 |
|
|
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan |
| Sato Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Seren Pharmaceuticals Inc. announced today that Sato Pharma and Eisai will co-promote a new triazole class oral antifungal agent (development code: BFE1224, "the agent") containing the active ingredient fosravuconazole L-lysine ethanolate ("fosravuconazole") in Japan, based on an agreement between the three companies. more info >> |
|
| Friday, September 29, 2017 |
|
|
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting |
| In the subpopulation analysis, lenvatinib demonstrated efficacy based on extension of Overall Survival (OS) compared to sorafenib (nominal P = 0.026), with improvements also observed in Progression Free Survival (PFS), Time to Progression (TTP) and Objective Response Rate (ORR) (see table below). more info >> |
|
|
|
|
